Ashley Lakner, Head of Oncology Discovery at Roche, shared Oxford BioTherapeutics’s post on LinkedIn, adding:
“Exciting news in the fight against cancer!
I am pleased to share Roche’s collaboration with Oxford BioTherapeutics (OBT) to discover innovative antibody-based therapeutics for patients in need.”
Quoting Oxford BioTherapeutics‘s post:
“OBT is pleased to announce that it has entered into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer. This collaboration will leverage our proprietary target discovery platform, OGAP-Verify, combined with Roche’s deep expertise translating insights into potential new treatments for patients.
Together, we aim to accelerate the development of innovative therapies that address major unmet patient needs in oncology.
Read the full press release here.”
